S&P 500   0.62 (-3.91%)
DOW   0.62 (-3.91%)
QQQ   260.37 (+0.71%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
GOOGL   1,520.86 (+0.57%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
F   6.36 (+4.78%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
S&P 500   0.62 (-3.91%)
DOW   0.62 (-3.91%)
QQQ   260.37 (+0.71%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
GOOGL   1,520.86 (+0.57%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
F   6.36 (+4.78%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
S&P 500   0.62 (-3.91%)
DOW   0.62 (-3.91%)
QQQ   260.37 (+0.71%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
GOOGL   1,520.86 (+0.57%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
F   6.36 (+4.78%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
S&P 500   0.62 (-3.91%)
DOW   0.62 (-3.91%)
QQQ   260.37 (+0.71%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
GOOGL   1,520.86 (+0.57%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
F   6.36 (+4.78%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
Log in

NYSEAMERICAN:CANFCAN-FITE BIOPHA/S Stock Price, Forecast & News

$1.84
-0.04 (-2.13 %)
(As of 07/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.80
Now: $1.84
$1.86
50-Day Range N/A
52-Week Range
$1.08
Now: $1.84
$4.95
Volume426,600 shs
Average Volume1.06 million shs
Market Capitalization$15.95 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases. The company's lead drug candidate is CF101 (Piclidenoson), which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 (Namodenoson) that is in Phase II clinical trials for the treatment of liver cancer and non-alcoholic fatty liver diseases, as well as for hepatocellular carcinoma and hepatitis C virus diseases; and CF602, which is in pre-clinical trial for the treatment of sexual dysfunction. Can-Fite BioPharma Ltd. has a collaborative research agreement with the Icahn School of Medicine for therapeutic discovery of liver diseases. The company was founded in 1994 and is headquartered in Petah-Tikva, Israel.
Read More
CAN-FITE BIOPHA/S logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.26 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:CANF
CUSIPN/A
Phone+972-3-9241114

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees7
Market Cap$15.95 million
Next Earnings Date9/4/2020 (Estimated)
OptionableOptionable

Receive CANF News and Ratings via Email

Sign-up to receive the latest news and ratings for CANF and its competitors with MarketBeat's FREE daily newsletter.

CAN-FITE BIOPHA/S (NYSEAMERICAN:CANF) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of CAN-FITE BIOPHA/S?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CAN-FITE BIOPHA/S in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for CAN-FITE BIOPHA/S.

When is CAN-FITE BIOPHA/S's next earnings date?

CAN-FITE BIOPHA/S is scheduled to release its next quarterly earnings announcement on Friday, September 4th 2020. View our earnings forecast for CAN-FITE BIOPHA/S.

How were CAN-FITE BIOPHA/S's earnings last quarter?

CAN-FITE BIOPHA/S (NYSEAMERICAN:CANF) released its quarterly earnings data on Monday, June, 1st. The biotechnology company reported ($0.72) earnings per share for the quarter, missing analysts' consensus estimates of ($0.59) by $0.13. The biotechnology company had revenue of $0.20 million for the quarter, compared to analyst estimates of $0.50 million. View CAN-FITE BIOPHA/S's earnings history.

What price target have analysts set for CANF?

1 brokers have issued 12 month price objectives for CAN-FITE BIOPHA/S's shares. Their forecasts range from $5.00 to $5.00. On average, they expect CAN-FITE BIOPHA/S's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 171.7% from the stock's current price. View analysts' price targets for CAN-FITE BIOPHA/S.

Has CAN-FITE BIOPHA/S been receiving favorable news coverage?

Media stories about CANF stock have trended somewhat negative on Tuesday, according to InfoTrie. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. CAN-FITE BIOPHA/S earned a news sentiment score of -1.5 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news about CAN-FITE BIOPHA/S.

Who are some of CAN-FITE BIOPHA/S's key competitors?

What other stocks do shareholders of CAN-FITE BIOPHA/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CAN-FITE BIOPHA/S investors own include NovaBay Pharmaceuticals (NBY), Opko Health (OPK), BIOLINERX LTD/S (BLRX), Gilead Sciences (GILD), Athersys (ATHX), Inovio Pharmaceuticals (INO), Iovance Biotherapeutics (IOVA), Novavax (NVAX), Protalix Biotherapeutics (PLX) and TransEnterix (TRXC).

Who are CAN-FITE BIOPHA/S's key executives?

CAN-FITE BIOPHA/S's management team includes the following people:
  • Dr. Ilan Cohn, Co-Founder & Chairman (Age 65)
  • Prof. Pnina Fishman, Scientific Founder, CEO & Director (Age 71)
  • Mr. Motti Farbstein, Chief Operating & Financial Officer (Age 55)
  • Dr. Sari Fishman Ph.D., VP of Bus. Devel. (Age 47)
  • Dr. Vibeke Strand M.D., FACP, FACR (USA), Sr. Clinical Advisor

What is CAN-FITE BIOPHA/S's stock symbol?

CAN-FITE BIOPHA/S trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CANF."

How do I buy shares of CAN-FITE BIOPHA/S?

Shares of CANF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is CAN-FITE BIOPHA/S's stock price today?

One share of CANF stock can currently be purchased for approximately $1.84.

How big of a company is CAN-FITE BIOPHA/S?

CAN-FITE BIOPHA/S has a market capitalization of $15.95 million. CAN-FITE BIOPHA/S employs 7 workers across the globe.

What is CAN-FITE BIOPHA/S's official website?

The official website for CAN-FITE BIOPHA/S is www.canfite.co.il.

How can I contact CAN-FITE BIOPHA/S?

CAN-FITE BIOPHA/S's mailing address is 10 Bareket Street, Kiryat Matalon P.O. Box 7537, PETAH TIKVA, 49170, Israel. The biotechnology company can be reached via phone at +972-3-9241114.

This page was last updated on 7/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.